COLONY STIMULATING FACTORS PRIOR AUTHORIZATION FORM





(form effective 1/6/2025)

Fax to PerformRxSM at **1-888-981-5202**, or to speak to a representative call **1-866-610-2774**.

PRIOR AUTHO	ORIZATION RE	QUEST INFORMAT	ION						
☐ New request	☐ Renewal request	Total # of page	s:						
Name of office contact:			Contact's p	Contact's phone number: LTC		LTC fac	C facility contact/phone:		
PATIENT INFO	ORMATION								
Patient name:				Patient ID #:			DOB:		
Street address:									
Apt #: City/state/zip:				Phone:					
PRESCRIBER	INFORMATIO	N							
Prescriber name:									
Specialty:				NF	1:		State license #:		
Street address:									
Suite #:	City/state/zip	p:							
Phone:				Fax:					
CLINICAL INF	ORMATION								
Medication requeste									
Preferred:				Non-Preferred:					
☐ Fulphila (pegfilgrastim-jmdb) Syringe				☐ Fylnetra (pegfilgrastim-pbbk) Syringe					
☐ Granix (tbo-filgrastim) Syringe				☐ Leukine (sargramostim) Vial					
☐ Granix (tbo-filgrastim) Vial				☐ Neulasta (pegfilgrastim) Onpro					
☐ Neupogen (filgrastim) Syringe				☐ Neulasta (pegfilgrastim) Syringe					
☐ Neupogen (filgrastim) Vial				☐ Nivestym (filgrastim-aafi) Syringe					
☐ Releuko (filgrastim-ayow) Syringe				☐ Nivestym (filgrastim-aafi) Vial					
☐ Releuko (filgrastim-ayow) Vial				☐ Nyvepria (pegfilgrastim-apgf) Syringe					
				☐ Rolvedon (eflapegrastim-xnst) Syringe					
				☐ Stimufend (pegfilgrastim-fpgk) Syringe					
				Udenyca (pegfilgrastim-cbvq) Autoinjector					
					yca (pegfilgrastim-cbvq) Onbod	•			
					yca (pegfilgrastim-cbvq) Syring	е			
				☐ Zarxio (filgrastim-sndz) Syringe					
				□ Ziext	enzo (pegfilgrastim-bmez) Syrir				
Dosage form (e.g., v	vial, syringe, kit, etc.)):		-		8	Strength:		
Dose/route/frequency:				Qı	uantity:	F	Refills:		
Diagnosis (submit a	locumentation):					[Ox code <u>(required)</u> :		
Beneficiary's height	:	in. / cm	Beneficiary's weight:		lbs / kg	E	BSA (Leukine only):	m²	



NITIAL REQUESTS
Complete all sections that apply to the beneficiary and this request. Check all that apply and submit documentation for each item.
☐ Has recent results of a CBC with differential (submit copy of results) ☐ Is or will be receiving chemotherapy. List chemotherapy regimen: ☐ Is or will be receiving radiation therapy: Dates or planned dates of radiation: ☐
. For a NON-PREFERRED Colony Stimulating Factor (CSF): ☐ Has a history of trial and failure of or a contraindication or an intolerance to the preferred Colony Stimulating Factors that are approved or medically accepted for treatment of the beneficiary's diagnosis (Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.) List medications tried:
Prophylaxis of chemotherapy-induced febrile neutropenia: Has at least 1 of the following risk factors for the development of febrile neutropenia: Age >65 years Recent surgery History of febrile neutropenia Poor liver or kidney function Current infection or open wound Previous chemotherapy or radiation Cardiovascular disease Poor nutritional or performance status other:
☐ Receiving or will receive a chemotherapy regimen with an expected incidence of neutropenia >20% ☐ For pegfilgrastim (Neulasta, Udenyca, etc.): Last date of chemo: Planned administration date: Next expected chemo date:
6. <u>Treatment of febrile neutropenia:</u> ☐ Received or is receiving myelosuppressive anticancer drugs associated with neutropenia ☐ Is at high risk for infection-related complications
Bone marrow transplant: Has a non-myeloid malignancy and is undergoing myeloablative chemotherapy to be followed by bone marrow transplant Planned transplant date: Has non-Hodgkin's lymphoma, acute lymphoblastic leukemia, or Hodgkin's lymphoma and had an autologous bone marrow transplant Transplant date:
5. Stem cell transplant: Is planned for autologous peripheral stem cell transplant Is planned for allogeneic peripheral stem cell transplant Will be using the requested medication in combination with plerixafor (also complete Mozobil prior authorization form) or another stem cell mobilizer Planned leukapheresis date: Planned transplant date: Had an autologous or allogeneic peripheral stem cell transplant Transplant date:
6. Acute myeloid leukemia: CSF will be used following induction chemotherapy CSF will be used following consolidation chemotherapy other:
 ✓. Hematopoietic syndrome of acute radiation syndrome: ☐ Suspected or confirmed exposure to a radiation dose >2 gray (Gy)
3. <u>Severe chronic neutropenia — specify type:</u> □ congenital neutropenia □ cyclic neutropenia □ idiopathic neutropenia □ Experiencing symptoms of neutropenia
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION

Prescriber signature:

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any telecopy is strictly prohibited.

Coverage by AmeriHealth First.

KF_244041800-2 Page 2 of 2